Stifel raised its price target on Cara Therapeutics (NASDAQ: CARA) to $20.00 (from $17.00) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Cara Therapeutics (CARA) PT Raised to $24 at H.C. Wainwright; 'Premier Partnership Incrementally De-Risks IV Korsuva'May 23, 2018 12:44 PM Cara Therapeutics (CARA) Bullish View Reiterated at Laidlaw Following Licence Agreement with Vifor Fresenius MedicalMay 23, 2018 11:00 AM Needham & Company Maintains Bullish View on Cara Therapeutics (CARA) Following IV CR845 License AgreementMay 23, 2018 10:26 AM Pre-Open Movers 05/23: (AVGR) (CARA) (TIF) Higher; (RRGB) (PFNX) (TCS) Lower (more...)May 23, 2018 9:23 AM Form 8-K Cara Therapeutics, Inc. For: May 23May 23, 2018 8:31 AM Cara Therapeutics (CARA) Reports Ex-US Licensing Agreement with Vifor Fresenius Medical Care Renal Pharma to Commercialize KORSUVA Injection May 23, 2018 6:09 AM Form 8-K Cara Therapeutics, Inc. For: May 17May 23, 2018 6:07 AM Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) Enter into Ex-U.S. Licensing Agreement to Commercialize KORSUVA™ Injection in Dialysis Patients with PruritusMay 23, 2018 6:00 AM